Advicenne SA
3MM
Company Profile
Business description
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Contact
262, rue du Faubourg Saint-Honor
Paris75008
FRAT: +33 185733620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Reassuring organic growth for undervalued ASX share
Efficiency gains are starting to make their mark.
stocks
Big IPOs are enticing but are they good investments?
Historically, buzzy debuts have been painful for buyers.
stocks
This defensive ASX listed REIT offers a 5% yield
Solid outlook underpinned by rent uplifts and development pipeline.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,697.90 | 138.70 | -1.57% |
| CAC 40 | 8,080.74 | 66.09 | -0.81% |
| DAX 40 | 25,463.81 | 272.43 | -1.06% |
| Dow JONES (US) | 49,097.06 | 1,101.11 | -2.19% |
| FTSE 100 | 10,452.68 | 98.49 | -0.93% |
| HKSE | 22,399.60 | 442.02 | -1.94% |
| NASDAQ | 23,879.20 | 550.69 | -2.25% |
| Nikkei 225 | 56,493.75 | 2,950.46 | -4.96% |
| NZX 50 Index | 14,107.41 | 139.84 | -0.98% |
| S&P 500 | 7,175.83 | 147.80 | -2.02% |
| S&P/ASX 200 | 8,599.70 | 130.70 | -1.50% |
| SSE Composite Index | 3,510.35 | 67.26 | -1.88% |